Abstract 875: Next generation clonal neoantigen targeting T cells, generated using the PELEUSTM bioinformatics platform and the VELOSTM manufacturing method show superior reactivity and phenotypic characteristics than classical TIL products
Eleni Kotsiou, Katy Newton, Sonal Varsani, Samra Turajlic(Royal Marsden NHS Foundation Trust), David Lawrence(Pfizer (United States)), Mariam Jamal‐Hanjani(CRUK Lung Cancer Centre of Excellence), Shreenal Patel, Pablo D. Becker(United Therapeutics (United Kingdom)), Theres Oakes(University College London), Martin D. Foster(Churchill Hospital), Andrew W. Craig(Queen's University), Jennine Mootien, Farah Islam(London Cancer), Joseph Robinson, Edward Samuel, Andrew R. Haynes(Mary Lyon Centre at MRC Harwell), Tie Zheng Hou, Lyra Del Rosario(Royal Marsden NHS Foundation Trust), Jane Robertson(Cancer Research UK), James L. Reading(CRUK Lung Cancer Centre of Excellence), Sergio A. Quezada(Memorial Sloan Kettering Cancer Center)
Cited by 3
Related Papers
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Resolving genetic heterogeneity in cancer
|Nature Reviews Genetics|2019|689